Savolitinib Clinical Trials

3 actively recruiting trials

No change since May 2026

Also known as: AZD6094, AZD6094, HMPL-504, volitinib, ORPATHYS

Pipeline

Phase 2: 2Phase 1/2: 1

Top Sponsors

The First Affiliated Hospital of Guangzhou Medical University1
Sun Yat-sen University1
Jeeyun Lee1

Indications

Cancer3
Lung Cancer2
Stomach Cancer, Adenocarcinoma1
Mutation1
Lung Cancer Stage III1

Other3 trials

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Phase 2

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Phase 2

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.